Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
Profound Medical will meet investors one-on-one at Lake Street’s BIG10 conference while highlighting its MRI-guided TULSA-PRO and Sonalleve platforms.
Rhea-AI Summary
Profound Medical (PROF) will participate in Lake Street Capital Markets’ “BIG10” 10th Annual Best Ideas Growth Conference on September 10, 2026, in New York City. Management will hold one-on-one investor meetings, and no webcast will be provided due to the event format.
Profound is a commercial-stage medical device company focused on interventional MRI (iMRI) procedures. Its flagship TULSA-PRO platform enables MRI-guided, incision-free prostate tissue ablation, supporting a range of personalized prostate cancer treatment strategies. The company also commercializes Sonalleve, an MRI-guided therapy for non-surgical treatment of pain palliation of bone metastases, desmoid tumors, osteoid osteoma, and certain gynecologic conditions such as uterine fibroids and adenomyosis.
TULSA-PRO is FDA-cleared in the United States for transurethral ultrasound ablation of prostate tissue and is also cleared in Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve has FDA HDE approval in the United States for osteoid osteomas in the extremities and is also cleared or approved in Europe, Canada, China, and Saudi Arabia.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 01 | Leadership appointment | Neutral | +0.0% | Richard Fabian appointed President; Mathieu Burtnyk moved to Chief Technology Officer |
| Aug 17 | Software launch | Positive | -1.2% | New TDC software added real-time interventional MRI control to TULSA-PRO |
| Aug 14 | Management change | Negative | -1.2% | Matthew Sobczyk became Interim CFO after Rashed Dewan stepped down |
| Aug 13 | Community launch | Positive | -0.6% | Company launched Let's Huddle patient community supporting prostate-care journeys |
| Aug 06 | Q2 earnings report | Positive | -6.7% | Revenue increased while margin expanded and full-year outlook was reiterated |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history showed negative reactions after the August 17 software announcement, August 13 community launch, and August 6 earnings release.
Key Terms
interventional mri medical
hde regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, announced today that management will participate in the Lake Street Capital Markets “BIG10” Conference on September 10, 2026 in New York City.
The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available.
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical (PROF) participate in Lake Street’s BIG10 Best Ideas Growth Conference?
Profound Medical is scheduled to participate in Lake Street Capital Markets’ “BIG10” 10th Annual Best Ideas Growth Conference on September 10, 2026, in New York City. Company management will hold one-on-one investor meetings during the event.
Will there be a webcast of Profound Medical’s participation at the Lake Street BIG10 conference?
No. The company states that due to the one-on-one meeting format of Lake Street’s “BIG10” Best Ideas Growth Conference, no webcast of Profound Medical’s participation will be available to the public.
What does Profound Medical (PROF) do in the field of MRI-guided therapy?
Profound Medical is a commercial-stage medical device company specializing in interventional MRI (iMRI) procedures. It develops and markets technologies like TULSA-PRO and Sonalleve to deliver precise, incision-free treatments guided by real-time MRI imaging.
What is TULSA-PRO and how is it used by Profound Medical (PROF)?
TULSA-PRO is Profound Medical’s flagship platform for MRI-guided, incision-free prostate tissue ablation. Physicians use the TULSA Procedure to see, ablate, and confirm therapy in real time, enabling personalized whole-gland, subtotal, hemi, multifocal, or focal prostate treatments.
In which markets is Profound Medical’s TULSA-PRO cleared for use?
TULSA-PRO is FDA-cleared in the United States for transurethral ultrasound ablation of prostate tissue. It is also cleared for use in Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, according to the company.
What is Sonalleve and what conditions can it treat for Profound Medical (PROF)?
Sonalleve is an MRI-guided therapy platform offering non-surgical treatment for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as gynecologic conditions including uterine fibroids and adenomyosis. It delivers targeted therapy with no incisions and typically faster recovery.
Where is Profound Medical’s Sonalleve technology approved or cleared for clinical use?
Sonalleve has FDA Humanitarian Device Exemption (HDE) approval in the United States for treating osteoid osteomas in the extremities. It is also cleared or approved in Europe, Canada, China, and Saudi Arabia for various indications.